<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01237379</url>
  </required_header>
  <id_info>
    <org_study_id>McNamara NARSAD</org_study_id>
    <nct_id>NCT01237379</nct_id>
  </id_info>
  <brief_title>Peroxisomal Defects and Familial Risk for Bipolar Disorder</brief_title>
  <official_title>Peroxisomal Defects and Familial Risk for Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to screen for peroxisome defects in child and adolescent&#xD;
      offspring of Bipolar Disorder I (BD-I) parents at different stages of risk for transitioning&#xD;
      to mania and following the onset of mania.&#xD;
&#xD;
      Prediction 1: Youth with an elevated risk for developing BD-I and first-episode manic&#xD;
      patients will exhibit graded deficits in measures of peroxisomal function compared with&#xD;
      healthy controls.&#xD;
&#xD;
      Prediction 2: Indices of peroxisomal function will be correlated with Red Blood Cells&#xD;
      Docosahexaenoic acid (DHA) composition.&#xD;
&#xD;
      Prediction 3: Graded deficits in measures of peroxisomal function will be inversely&#xD;
      correlated with manic and depression symptom severity scores.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Overall Study Design: This study entails collecting fasting venous blood (20 ml) from, and&#xD;
      administering the 'omega-3 questionnaire' to, subjects being recruited from ongoing National&#xD;
      Institute of Mental Health (NIMH)-sponsored trials within the Department of Psychiatry,&#xD;
      University of Cincinnati College of Medicine. Specifically, blood will be collected from 20&#xD;
      healthy controls (i.e., no personal or family history of any Axis I mood disorder according&#xD;
      to the Diagnostic and Statistical Manual of Mental Disorders-IV [DSM-IV]) and 20 asymptomatic&#xD;
      high-risk (i.e., have a biological parent with BD-I) adolescents (aged 10-18 years old)&#xD;
      recruited for study MH077138 (UC-IRB #: 07-04-10-03, BITREC Project 3; PI: DelBello), 20&#xD;
      ultra-high risk (i.e., have a biological parent with BD-I and a Major Depressive Disorder&#xD;
      (MDD) diagnosis) recruited for study MH083924 (UC-IRB #: 04-09-15-03, CO-Principal&#xD;
      Investigators DelBello/McNamara), and 20 adolescents who are admitted for their first&#xD;
      hospitalization and who have a diagnosis of BD-I recruited for study MH080973 (UC-IRB #:&#xD;
      08-10-30-01, Principal Investigator: DelBello). Blood will then be processed, and&#xD;
      de-identified tubes sent to the Kennedy Krieger Institute, Peroxisomal Diseases Section, to&#xD;
      determine the following measures of peroxisomal function: (1) plasma very long chain fatty&#xD;
      acids (C24:0 &amp; C26:0) concentrations, (2) plasma bile acid C27 intermediate&#xD;
      (dehydrocrepenynic acid {DHCA},tetrahydrocannabinolic acid {THCA})concentrations, (3) plasma&#xD;
      pipecolic acid concentrations, and (4) Red Blood Cell (RBC) plasmalogen concentrations.&#xD;
      Additionally, RBC fatty acid composition will be determined by gas chromatography, and&#xD;
      platelet function and plasma inflammatory markers assayed using commercially available kits&#xD;
      according to manufacturer's instructions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Youth with an elevated risk for developing BD-I and first-episode manic patients will exhibit graded deficits in measures of peroxisomal function compared with healthy controls.</measure>
    <time_frame>1 day</time_frame>
    <description>Prediction 1: Youth with an elevated risk for developing BD-I and first-episode manic patients will exhibit graded deficits in measures of peroxisomal function compared with healthy controls.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>peroxisomal function will be inversely correlated with manic and depression symptom severity scores.</measure>
    <time_frame>1 day</time_frame>
    <description>Prediction 3: Graded deficits in measures of peroxisomal function will be inversely correlated with manic and depression symptom severity scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indices of peroxisomal function will be correlated with RBC DHA composition.</measure>
    <time_frame>1 day</time_frame>
    <description>Prediction 2: Indices of peroxisomal function will be correlated with RBC DHA composition.</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Mania</condition>
  <arm_group>
    <arm_group_label>Health Controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar Patients with High-Risk of Mania</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bipolar Patients with Ultra-High Risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>First Manic Episode Bipolar Youth</arm_group_label>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Laboratory methods: The gas chromatography procedure used to determine red blood cell fatty&#xD;
      acid composition. Briefly, total fatty acid composition will be determined. Indices of&#xD;
      peroxisome function, including (1) plasma very long chain fatty acids concentrations, (2)&#xD;
      plasma bile acid C27 intermediate concentrations, (3) plasma pipecolic acid concentrations,&#xD;
      and (4) RBC plasmalogen concentrations, will be determined by liquid chromatography tandem&#xD;
      mass spectrometry and gas chromatography. Plasma cytokine and C-Reactive Protein&#xD;
      (CRP)concentrations will be determined. All blood analyses will be performed by a technician&#xD;
      blinded to diagnostic group identity.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects: In order to accomplish this aim, 20 healthy controls, 20 high-risk, 20 ultra-high&#xD;
        risk, and 20 first-episode manic youth (ages 10-18 years old) will be recruited at a rate&#xD;
        of 1 subject/group per month over the first 20 months. Subjects being recruited from the&#xD;
        following IRB approved NIMH-sponsored trials: MH077138 (UC-IRB #: 07-04-10-03, BITREC&#xD;
        Project 3; PI: DelBello), MH083924 (UC-IRB #: 04-09-15-03, CO-PIs DelBello/McNamara), and&#xD;
        MH080973 (UC-IRB #: 08-10-30-01, PI: DelBello).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subject characteristics: All subjects will be 10-18 year old males and females. Up to 80&#xD;
        patients will be enrolled in this study. Subjects will be screened according to previously&#xD;
        approved individual study criteria (UC-IRB #: 07-04-10-03; 04-09-15-03; 08-10-30-01).&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  10 -18 year old males &amp; females&#xD;
&#xD;
          -  Based on currently enrolled study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Based on currently enrolled study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert McNamara, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>November 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2010</study_first_posted>
  <last_update_submitted>December 19, 2014</last_update_submitted>
  <last_update_submitted_qc>December 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert McNamara</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

